

Market Announcement

12 June 2026

Cynata Therapeutics Limited (ASX: CYP) – Trading Halt

Trading in the securities of Cynata Therapeutics Limited ('CYP') will be halted at the request of CYP, pending the release of an announcement by CYP.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Tuesday, 16 June 2026; or
- the release of the announcement to the market.

CYP's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

ASX ANNOUNCEMENT

12 June 2026

ASX Compliance
Level 50, South Tower
Rialto, 525 Collins Street
Melbourne VIC 3000

By email: tradinghaltmelbourne@asx.com.au

By email: melissa.kostopoulos@asx.com.au

Request for Trading Halt

Cynata Therapeutics Limited (“**Cynata**” or “the **Company**”) (ASX:CYP) requests that its securities be placed into an immediate trading halt.

In accordance with Listing Rule 17.1, the Company advises:

- (a) the trading halt is requested pending a material announcement by Cynata regarding clinical trial results for the Phase 3 Osteoarthritis Trial and the Phase 2 Graft Versus Host Disease Trial;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company making an announcement in relation to the clinical trial results and the commencement of trading on Tuesday, 16 June 2026;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Group](#).